AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

The new devices – NovoPen 6 and NovoPen Echo Plus – are insulin self-injection pens ... connected insulin pens aim to empower people to better understand their diabetes management, have ...